Amisulpride-induced acute akathisia in OCD: An example of dysfunctional dopamine-serotonin interactions?

Journal of Psychopharmacology

Volumn 26, Issue 6, 2012, Pages 887-890

  Ersche, Karen D ^a   Cumming, Paul ^b   Craig, Kevin J ^a   Müller, Ulrich ^a   Fineberg, Naomi A ^c   Bullmore, Edward T ^a,d   Robbins, Trevor W ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF MUNICH   (Germany)

^c QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Akathisia; antipsychotics; dopamine; obsessive compulsive disorder; serotonin

Indexed keywords

AMISULPRIDE; CITALOPRAM; DOPAMINE; SEROTONIN;

ACUTE DISEASE; ADVERSE OUTCOME; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HUMAN; MALE; MENTAL TASK; MOLECULAR INTERACTION; MONOTHERAPY; NEGATIVE FEEDBACK; NEUROPATHOLOGY; OBSESSIVE COMPULSIVE DISORDER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROTONINERGIC SYSTEM; SINGLE DRUG DOSE; TASK PERFORMANCE; YALE BROWN OBSESSIVE COMPULSIVE SCALE;

ADULT; AKATHISIA, DRUG-INDUCED; DOPAMINE; FEMALE; HUMANS; MALE; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN; SEROTONIN UPTAKE INHIBITORS; SULPIRIDE;

EID: 84862149568     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881111405363     Document Type: Article

References (22)

1. Aron AR, Fletcher PC, Bullmore ET, Sahakian BJ, Robbins TW. Stop-signal inhibition disrupted by damage to right inferior frontal gyrus in humans. Nat Neurosci. 2003 ; 6: 115-116
2. Bandelow B, Zohar J, Hollander E, Kasper S, Moller HJ. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders-first revision. World J Biol Psychiatry. 2008 ; 9: 248-312
3. Beck AT, Steer RA, Brown GK Manual for Beck Depression Inventory-II. San Antonio, TX: Psychological Corporation ; 1996 :
4. Chamberlain SR, Muller U, Blackwell AD, Clark L, Robbins TW, Sahakian BJ. Neurochemical modulation of response inhibition and probabilistic learning in humans. Science. 2006 ; 311: 861-863
5. Chouinard G, Sultan S. A case of Parkinson's disease exacerbated by fluoxetine. Hum Psychopharmacol. 1992 ; 7: 63-66
6. Denys D, van der Wee N, Janssen J, de Geus F, Westenberg HGM. Low level of dopaminergic D2 receptor binding in obsessive-compulsive disorder. Biol Psychiatry. 2004 ; 55: 1041-1045
7. Fineberg NA, Gale TM. Evidence-based pharmacotherapy of obsessive-compulsive disorder. Int J Neuropsychopharmacol. 2005 ; 8: 107-129
8. Fineberg NA, Gale TM, Sivakumaran T. A review of antipsychotics in the treatment of obsessive compulsive disorder. J Psychopharmacol. 2006 ; 20: 97-103
9. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown Obsessive Compulsive Scale.1. Development, use, and reliability. Arch Gen Psychiatry. 1989 ; 46: 1006-1011
10. Koliscak LP, Makela EH. Selective serotonin reuptake inhibitor-induced akathisia. J Am Pharm Assoc. 2009 ; 49: E28 - E38
11. Kugaya A, Seneca NM, Snyder PJ, Williams SA, Malison RT, Baldwin RM, et al. Changes in human in vivo serotonin and dopamine transporter availabilities during chronic antidepressant administration. Neuropsychopharmacology. 2003 ; 28: 413-420
12. Kumar R, Sachdev PS. Akathisia and second-generation antipsychotic drugs. Curr Opin Psychiatry. 2009 ; 22: 293-299
13. Mehta MA, Montgomery AJ, Kitamura Y, Grasby PM. Dopamine D2 receptor occupancy levels of acute sulpiride challenges that produce working memory and learning impairments in healthy volunteers. Psychopharmacology. 2008 ; 196: 157-165
14. Mundt JC, Marks IM, Shear MK, Greist JH. The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry. 2002 ; 180: 461-464
15. Nelson HE National Adult Reading Test Manual. Windsor, UK: NFER-Nelson ; 1982 :
16. Pogarell O, Poepperl G, Mulert C, Hamann C, Sadowsky N, Riedel M, et al. SERT and DAT availabilities under citalopram treatment in obsessive-compulsive disorder (OCD). Eur Neuropsychopharmacol. 2005 ; 15: 521-524
17. Poyurovsky M. Acute antipsychotic-induced akathisia revisited. Br J Psychiatry. 2010 ; 196: 89-91
18. Poyurovsky M, Pashinian A, Weizman R, Fuchs C, Weizman A. Low-dose mirtazapine: A new option in the treatment of antipsychotic-induced akathisia. A randomized, double-blind, placebo- and propranolol-controlled trial. Biol Psychiatry. 2006 ; 59: 1071-1077
19. Reimold M, Smolka MN, Zimmer A, Batra A, Knobel A, Solbach C, et al. Reduced availability of serotonin transporters in obsessive-compulsive disorder correlates with symptom severity-a [C-11]DASB PET study. J Neural Transm. 2007 ; 114: 1603-1609
20. Sachdev PS, Brüne M. Animal models of acute drug-induced akathisia-a review. Neurosci Biobehav Rev. 2000 ; 24: 269-277
21. Sahakian BJ, Morris RG, Evenden JL, Heald A, Levy R, Philpot M, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain. 1988 ; 111: 695-718
22. Swainson R, Rogers RD, Sahakian BJ, Summers BA, Polkey CE, Robbins TW. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia. 2000 ; 38: 596-612